Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX nanoparticles with whole-brain radiotherapy for multiple brain metastases
2018-001879-20Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- May 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of AGuIX in brain metastases and Nonhematologic neoplasms (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoints: Objective intracranial response at 6 weeks and Objective intracranial response at 3 months. Started May 2018; status: completed.
02
Drugs
AGuIX
03
Conditions
brain metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on 2018-001879-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001879-20.